Company intelligence / Profile preview

Ascletis Pharma Inc.

Hangzhou（杭州）, Zhejiang（浙江省）, 中国（China）ascletis.com ↗

Ownership: Public · 1672.HK
Employees: ~231
Development stage: Phase 2

Overview

Ascletis has demonstrated positive topline results in U.S. Phase Ib studies of its lead candidate ASC30—a first-in-class small molecule GLP‑1R agonist with both oral and subcutaneous dosing options for obesity. No serious adverse events were reported in recent trials. The company also markets antiviral drugs for hepatitis C and develops candidates across metabolic diseases and oncology

Therapeutic areas: OncologyEndocrinologyDermatologyGastroenterologyInfectious Diseases
Modalities: Small molecules (notably oral and injectable small molecule GLP‑1R agonists)antiviral agents
Industry: Biotech

Drug pipeline

30 assets

ASC30

29 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Ascletis Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascletis Pharma Inc..

Explore the full profile